药商领袖强调韩国不断增长的生物技术产业的细胞疗法和人工智能。 Pharma leaders highlight cell therapy and AI in South Korea's growing biotech industry.

全球制药领导人将细胞疗法、AI驱动的药物开发、数字保健和美学医学确定为韩国生物技术工业的关键领域。 Global pharmaceutical leaders identified cell therapy, AI-driven drug development, digital healthcare, and aesthetic medicine as key areas for South Korea's biotech industry. 利用韩国干细胞研究优势的细胞疗法被视为一个重大机会。 Cell therapy, leveraging Korea's strengths in stem cell research, is seen as a major opportunity. 该行业需要可靠的数据和临床基础设施来吸引全球投资者,并建议各公司将重点放在高价值战略上,以便在300亿美元的美学药品市场中增长。 The industry needs trustworthy data and clinical infrastructure to attract global investors, and companies are advised to focus on high-value strategies to grow in the $30 billion aesthetic medicine market.